Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Finished

GUTOCINS Oral oxytocin for abdominal pain

Coordinator
Universitat Wien, Austria
Runs
1 June 2023 to 30 November 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101113137

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic abdominal pain is a widespread debilitating condition commonly associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). IBS and IBD affect more than 10% of the global population, leaving a severe and steadily growing socio-economic burden on society (€115 billion/year in Europe in direct and indirect health care costs). Adequate pain management for these conditions is imperative but remains challenging since classical analgesics are poorly effective, associated with adverse effects, and can even exacerbate disease progression.

In this project, we will advance a new class of gut-stable peptide analgesics to target abdominal pain at its origin in the gut. This represents a highly innovative treatment strategy with a large safety window due to its gut-specific action and negligible risk of systemic off-target effects. It also addresses a long-standing problem in the peptide therapeutics industry, namely the lack of oral peptide drugs. The objective of this project is to optimise our patented lead compounds towards oral drug candidates and generate robust and supporting preclinical data for clinical translation.

The proof-of-concept data will then be used to engage with industry partners and other supporters to advance these drug candidates into the clinic for the treatment of chronic abdominal pain. Our gut-specific treatment approach along with this new class of analgesics could induce a highly desired paradigm shift in how to treat chronic abdominal pain and gastrointestinal disorders, an area with unprecedented unmet medical need.

This could benefit millions of people worldwide, improve their quality of life, and help reduce the substantial socio-economic burden that chronic abdominal pain has on society.

Topics

Who is involved

OrganisationCityCountryRole
Universitat WienWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI